Healthcare & Life Sciences
Cytoki Pharma
Denmark
aliveseries-a
series-a
Stage
1
Investors
About
Cytoki Pharma develops protein therapeutics targeting diseases characterized by epithelial injury, including a licensed long-acting IL-22 program for inflammatory bowel disease and a Phase 2 clinical program (CK-0045) for obesity and type 2 diabetes.
Explore Cytoki Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.